An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

NCT05262309 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Respiratory Infection
COVID-19 Pneumonia
Covid19

Interventions

DRUG: Pamrevlumab

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS